ENTER


Полный размерЗакрыть

Analysis of the Relationship between the Content of Serum Fractalkine and Condition of the Retina in Patients with Type 2 Diabetes Mellitus and Diabetic Macular Edema

Details
Written by Super User
Published: 14 July 2019
Hits: 910


https://doi.org/10.30702/Ophthalmology.2019/09.072033

Suk S.А.1, 2, Rykov S.O.1, Kyryliuk M.L.3


1Shupyк National Medical Academy of Postgraduate Education, Kyiv, Ukraine
2Kyiv City Clinical Ophthalmological Hospital, Kyiv, Ukraine
3Ukrainian Scientific and Practical Center of Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of Health of Ministry of Public Health of Ukraine, Kyiv, Ukraine 

Abstract 

Background. The work is dedicated to the study of the content of serum fractalkine in patients with type 2 diabetes mellitus (DMT2) in conjunction with instrumental indicators of the condition of macula layers in various forms of diabetic macular edema (DME).

Objective. Examinations were conducted in 82 patients with DMT2 (145 eyes) designated to one of four groups according to the form of DME.

Methods. ANOVA and regression analysis, as well as the method of constructing logistic regression models were used.

Results. In patients with DMT2, the chances of having high area thickness significantly reduce per each 1 ng/ml of serum fractalkine increase. The threshold value of the serum fractalkine for the high area thickness value (≥ 354 micron) is ≤ 1.632 ng/ml with a test sensitivity of 42.9 % and specificity of 88.4 %.

Conclusion. Fractalkine has protective role in the development of DME and possesses therapeutic potential in reducing the pathogenic effect of DMT2 on the retinal neurovascular unit.

Keywords: fractalkine, diabetic macular edema, type 2 diabetes mellitus.

REFERENCES 

  1. Oliveira MIA, de Souza EM, de Oliveira Pedrosa F, et al. RAGE receptor and its soluble isoforms in diabetes mellitus complications. J Bras Patol Med Lab. 2013;49:97–108. http://dx.doi.org/10.1590/S1676-24442013000200004
  2. Saf SZ, Qvist R, Kumar S, et al. Molecular mechanisms of diabetic retinopathy, general preventive strategies, and novel therapeutic targets. BioMed Research International. 2014; 2014:801269.
  3. Kronenberg HM, Williams RH. Williams Textbook of Endocrinology. 11th ed. Philadelphia, PA: Elsevier Saunders; 2008.
  4. Grigsby JG, Cardona SM, Pouw CE, et al. The role of microglia in diabetic retinopathy. J Ophthalmol. 2014;2014:705783. http://dx.doi.org/10.1155/2014/705783
  5. National Eye Institute [Internet]. Facts About Diabetic Eye Disease; [about 1 screen]. Available from: https://nei.nih.gov/health/diabetic/retinopathy
  6. Rangasamy S, McGuire PG, Das A. Diabetic retinopathy and inflammation: novel therapeutic targets. Middle East Afr J Ophthalmol. 2012;19(1):52–9. http://dx.doi.org/10.4103/ 0974-9233.92116
  7. Wisse BE. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol. 2004;15:2792–800.
  8. Malachkova NV, Kyryliuk ML, Komarovska IV. Serum adiponectin levels in obese type 2 diabetic patients with diabetic retinopathy. J ophthalmol (Ukraine). 2017;5:39–44. http://dx. doi.org/10.31288/oftalmolzh201753944
  9. Malachkova NV, Kyryliuk ML, Komarovska IV. Association between serum resistin level and diabetic retinopathy in obese patients with type 2 diabetes mellitus. J ophthalmol (Ukraine). 2017;4:9–13. http://dx.doi.org/10.31288/oftalmolzh20174913
  10. Serdiuk VN, Kyryliuk ML, Ishchenko VA. Mathematical substantiation of the method for assessing the risk of progression of diabetic retinopathy with serum leptin determination in patients with metabolic syndrome and diabetes mellitus. J ophthalmol (Ukraine). 2018;2: 17–22. http://dx.doi.org/10.31288/oftalmolzh/2018/2/1721
  11. Serdiuk VN, Kyryliuk ML, Pylypenko LYu. Activity of plasminogen activator inhibitor-1 in blood of patients with metabolic syndrome depending on a stage of diabetic retinopathy. J ophthalmol (Ukraine). 2018;3:52–6. http://dx.doi.org/10.31288/oftalmolzh201835256
  12. Bringmann A, Iandiev I, Pannicke T, et al. Cellular signaling and factors involved in Müller cell gliosis: neuroprotective and detrimental effects. Prog Retin Eye Res. 2009;28:423–51.
  13. Simó R, Hernández C. European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR). Neurodegeneration in the diabetic eye: new insights and therapeutic perspectives. Trends Endocrinol Metab. 2014;25:23–33.
  14. Bringmann A, Pannicke T, Grosche J, et al. Müller cells in the healthy and diseased retina. Prog Retin Eye Res. 2006;25:397–424.
  15. Ascaso FJ, Huerva V, Grzybowski A. The role of inflammation in the pathogenesis of macular edema secondary to retinal vascular diseases. Mediators Inflamm. 2014;2014:432685.
  16. Zeng HY, Green WR, Tso MO. Microglial activation in human diabetic retinopathy. Arch Ophthalmol. 2008;126:227–32.
  17. Pelino CJ, Pizzimenti JJ. Contemporary care protocols for DR and DME. Rev Optom. 2012;149(8):90–9.
  18. Boyer DS. Insights into the pathophysiology of diabetic macular edema. A growing body of scientific evidence reveals multiple therapeutic targets. Supplement to retina today. 2015 November/December;12–15.
  19. Kuhtina NB, Aref’eva TI, Ruleva NYu, et al. Peptidnye fragmenty hemokinovogo domena fraktalkina: vliyanie na migraciyu monocitov cheloveka. Bioorg Himiya. 2012;38(6):660–6. 
  20. Schall T. Fractalkine – a strange attractor in the chemokine landscape. Immunol Today. 1997;18(4):147.
  21. Bazan JF, Bacon KB, Hardiman G. A new class of membrane-bound chemokine with a CX3C motif. Nature. 1997;385(6617):640–4.
  22. Mesnyankina OA, Yanchevskaya EY, Ben M. [Fractalkine: pathogenic role and diagnostic capabilities]. Kuban Scientific Medical Bulletin. 2017;1(2):148–51. (in Russian). https://doi. org/10.25207/1608-6228-2017-2-148-151
  23. Imai T, Hieshima K, Haskell C, et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell. November 1997;91(4):521–30. https://doi.org/10.1016/S0092-8674(00)80438-9. PMID 9390561
  24. Shah R, Hinkle CC, Ferguson JF, et al. Fractalkine is a novel human adipochemokine associated with type 2 diabetes. Diabetes. 2011;60:1512–8.
  25. Atlas of Genetics and Cytogenetics in Oncology and Haematology [Internet]. ATLAS; c2019. CX3CR1 (C-X3-C motif chemokine receptor 1); [about 1 screen]. Available from: http://atlasgeneticsoncology.org/Genes/GC_CX3CR1.html
  26. Sawai H, Park YW, He X, et al. Fractalkine mediates T cell-dependent proliferation of synovial fibroblasts in rheumatoid arthritis. Arthritis Rheum. 2007;56(10):3215–25.
  27. Perros F, Dorfmuller P, Souza R, et al. Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension. Eur Respir J. 2007;29(5):937–43.
  28. Hatori K, Nagai A, Heisel R, et al. Fractalkine and fractalkine receptors in human neurons and glial cells. J. Neurosci Res. 2002;69(3):418–26.
  29. White GE, Tan TC, John AE, et al. Fractalkine has antiapoptotic and proliferative effects on human vascular smooth muscle cells via epidermal growth factor receptor signaling. Cardiovascular Research. 2010;85:825–35.
  30. Beli E, Dominguez JM 2nd, Hu P, et al. CX3CR1 deficiency accelerates the development of retinopathy in a rodent model of type 1 diabetes. J Mol Med (Berl). 2016;94:1255–65. https://doi.org/10.1007/s00109-016-1433-0
  31. Cardona AE, Pioro EP, Sasse ME, et al. Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci. 2006;9:917–24.
  32. Cardona SM, Mendiola AS, Yang YCh, et al. Disruption of Fractalkine Signaling Leads to Microglial Activation and Neuronal Damage in the Diabetic Retina. ASN Neuro. 2015; 7(5):1759091415608204. https://doi.org/10.1177/1759091415608204
  33. American Academy of Ophthalmology [Internet]. San Francisco: AAO; c2019 [Updated 2017 Dec]. Diabetic Retinopathy; [about 1 screen]. Available from: www.aao.org/ppp
  34. Altman DG, Machin D, Bryant TN, Gardner MJ, editors. Statistics with confidence: confidence intervals and statistical guidelines. London: BMJ Books; 2003.
  35. Jekel JF, Katz DL, Elmore JG, Dorothea MG. Epidemiology, biostatistics, and preventive medicine. 3d ed. Philadelphia: Saunders Elsevier; 2007.
  36. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.
  37. Ransohoff RM, Cardona AE. The myeloid cells of the central nervous system parenchyma. Nature. 2010;468:253–62.
  38. Aloisi F. Immune function of microglia. Glia. 2001;36:165–79.
  39. Benveniste EN. Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis. Journal of Molecular Medicine. 1997;75:165–73.
  40. Zabel MK, Zhao L, Zhang Y, et al. Microglial phagocytosis and activation underlying photoreceptor degeneration is regulated by CX3CL1-CX3CR1 signaling in a mouse model of retinitis pigmentosa. Glia. 2016;64:1479–91.
  41. Mastropasqua R, D’Aloisio R, Di Nicola M, et al. Relationship between aqueous humor cytokine level changes and retinal vascular changes after intravitreal aflibercept for diabetic macular edema. Scientific Reports. 2018;8:16548. https://doi.org/10.1038/s41598-018-35036-9
  42. Muftuoglu IK, Mendoza N, Gaber R, et al. Integrity of outer retinal layers after resolution of central involved diabetic macular edema. Retina. 2017;37:2015–24.

 

Received: 27 March 2019

Published: April 2019